NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today re

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 202

FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2

PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026

Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average tradin

Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, roy

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today rep

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today re

Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, levera

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Confer

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist"

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimila

Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering

By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 mi

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today r

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy a

SG Americas Securities LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and

Protagonist Therapeutics earns a Buy rating, driven by Icotyde's FDA approval and robust near-term c

Leerink Partners analyst Faisal Khurshid maintains Protagonist Therapeutics (NASDAQ:PTGX) with a

Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and r

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competiti

Goldman Sachs analyst Richard Law maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Neutra

  During Monday's trading, 1214 companies set new 52-week lows.

  On Wednesday, 216 stocks hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

    During Wednesday's morning trading, 125 companies set new 52-week highs.

    Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs.

    During Wednesday's morning trading, 251 companies set new 52-week highs.

  On Wednesday morning, 198 companies hit new 52-week highs.